8-K: bioAffinity Regains Nasdaq Compliance, Avoids Delisting

bioAffinity Technologies has announced it has regained full compliance with Nasdaq's listing requirements, ensuring its common stock and warrants continue trading.

Summary

• Received a letter from Nasdaq on October 14, 2025, confirming compliance with Listing Rule 5550(a)(2) (Minimum Bid Price Rule) and 5550(b)(1) (Minimum Stockholders Equity Rule).
• The company's common stock (BIAF) and warrants (BIAFW) will continue to trade on the Nasdaq Capital Market.
• Nasdaq will subject the company to a mandatory panel monitor for a period of one year.
• If the company fails to comply with the Minimum Stockholders Equity Rule within the one-year monitoring period, it will not be permitted additional time to regain compliance, though it can request a new hearing before delisting.
• Issued a press release on October 15, 2025, announcing the compliance.
• CyPath Lung, the company's commercially available test for early-stage lung cancer, demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules (less than 20 millimeters).

Sentiment

Score: 7

Explanation: The company successfully resolved a significant listing compliance issue, which is a strong positive. However, the one-year monitoring period and the stricter conditions for future non-compliance introduce a degree of ongoing risk, preventing a higher score.

Positives

• Regained full compliance with Nasdaq's minimum bid price ($1.00 per share) and minimum stockholders' equity ($2.5 million) listing requirements.
• Securities will continue to trade on the Nasdaq Capital Market, maintaining market access and liquidity.
• CyPath Lung test shows strong performance with 92% sensitivity, 87% specificity, and 88% accuracy for early-stage lung cancer detection.

Negatives

• Subject to a mandatory one-year panel monitor by Nasdaq.
• No additional time will be granted to regain compliance with the Minimum Stockholders Equity Rule if it fails again within the monitoring period, though a new hearing can be requested.

Risks

• Failure to maintain compliance with Nasdaq's Minimum Stockholders Equity Rule within the one-year monitoring period could lead to delisting without additional time to regain compliance.
• General risks associated with forward-looking statements, as detailed in the company's Form 10-K for the year ended December 31, 2024, and its subsequent SEC filings.

Future Outlook

The company aims to focus on advancing its CyPath Lung test for lung cancer and its broader pipeline of noninvasive diagnostics while building shareholder value for the long term. It also needs to maintain compliance with Nasdaq's continued listing standards.

Management Comments

• "We are pleased to have regained full compliance with Nasdaq’s listing standards."
• "Maintaining our Nasdaq listing allows us to focus on advancing our CyPath Lung test for lung cancer and our broader pipeline of noninvasive diagnostics while also building shareholder value for the long term." Maria Zannes, President and Chief Executive Officer

Industry Context

The biotechnology industry, particularly in diagnostics, relies heavily on market access and investor confidence. Maintaining a Nasdaq listing is crucial for companies like bioAffinity Technologies to attract capital, maintain liquidity, and enhance visibility for their innovative diagnostic solutions such as CyPath Lung, which addresses a significant need in early-stage cancer detection.

Stakeholder Impact

• Shareholders: Positive impact by maintaining Nasdaq listing, ensuring liquidity and market access for common stock and warrants. Reduced risk of delisting.
• Employees: Stability and continued focus on product development (CyPath Lung) and pipeline.
• Customers/Patients: Continued development and availability of CyPath Lung, an early-stage lung cancer diagnostic.

Next Steps

• Continue advancing the CyPath Lung test for lung cancer.
• Develop the broader pipeline of noninvasive diagnostics.
• Maintain compliance with Nasdaq's Minimum Stockholders Equity Rule during the one-year monitoring period.
• Build shareholder value for the long term.

Key Dates

Recommendation

While regaining Nasdaq compliance is a significant positive, removing the immediate delisting threat, the company remains under a one-year mandatory panel monitor with stricter conditions for future non-compliance with the Minimum Stockholders Equity Rule. This introduces ongoing uncertainty. The focus on advancing CyPath Lung is positive, but without new financial performance data or significant strategic developments, a 'hold' recommendation is appropriate as investors await further operational and financial updates to assess long-term stability and growth.

Keywords

bioAffinity Technologies, BIAF, Nasdaq compliance, delisting, CyPath Lung, lung cancer diagnostics, biotechnology, SEC filing, 8-K, Minimum Bid Price Rule, Minimum Stockholders Equity Rule